Efruxifermin (FGF-21 mimetic)

Date not specified — Novo Nordisk’s “Investor highlights” webpage compiles key investor resources and upcoming events rather than reporting new clinical or financial data. It directs investors to quarterly financial results, announcements, investor presentations, calls and webcasts, and links to the Annual Report 2025 and related governance reports. The page also lists selected “Latest news” headlines with timestamps (e.g., 2026-06-03, 2026-05-27, 2026-05-26) and links to the news archive, but does not include the underlying announcements or results in-page. For investor events, Novo Nordisk notes its Annual General Meeting on 26 March 2026 at 14:00 (CET), followed by an informal shareholders’ meeting at approximately 17:00 (CET), and provides access to materials from Capital Markets Day 2024. Additional sections highlight services for private shareholders (Investor Portal, stock information, dividend and ownership-structure links) and a prompt to contact Investor Relations. Business significance: the page serves as a navigation hub for disclosures and scheduled investor communications.